Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

Last updated April 19, 2022

Key Points

Key Points

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status.

Diagnosis

...Diagnosis

...Newly Diagno...

...Oncotype DX (21-g...

...ecommendation 1.1If a patient has node-ne...

...mendation 1.2In the group of patients in...

...mendation 1.3In the group of patient...

...endation 1.4If a patient is postmenopa...

...ommendation 1.5In the group of patients in R...

...mmendation 1.6If a patient is premenopa...

...endation 1.7If a patient has node-positive breas...

...MammaPrint...

....8If a patient is older than 50 and h...

...ation 1.9If a patient is 50 years...

...1.10If a patient has low clinical ris...

Recommendation 1.11If a patient ha...

...EndoPredict (12...

...1.12If a patient is postmenopausal and...

...ation 1.13If a patient is premenopausal...

...dation 1.14If a patient has breast cancer...

Prosigna...

...n 1.15If a patient is postmenopausa...

...dation 1.16If a patient is premenopausal,...

....17If a patient is postmenopausal and h...

...ndation 1.18If a patient has node-positive breast...

...Mammostrat...

There is insufficient evidence to r...

If a patient has ER-positive, HER2...

...ent has ER-positive, HER2-negative, node-positive...

...Ki6...

...mendation 1.19If a patient is postm...

...1.20If a patient is postmenopausal and has breas...

...1.21Despite the limitations associated with Ki6...

...Immunohistochem...

....22If a patient has node-negative or n...

...uPA and PAI...

...as ER-positive, HER2-negative (nod...

...f a patient has HER2-positive breast cancer or tri...


Extended End...

...Oncotype DX, End...

...ation 1.23If a patient has node-ne...

...BCI...

...ommendation 1.24If a patient has no...

...tion 1.25If a patient has node-pos...

...C...

...tion 1.26If a patient is postmenopausal and...


...HER2-positi...

...Oncotype DX, EndoPr...

...commendation 1.27If a patient has HER...


...Emerging Bio...

...ommendation 1.28If a patient has node-negative o...

...PD-L1...

...dation 1.29If a patient has node-ne...

...Circula...

...endation 1.30If a patient has node-negative or no...

...Circulating Tumor D...

...mmendation 1.31If a patient has nod...


Table 1. Breast Cancer Biomarkers to Guide Ad...


...gure 1. Algorithm on Biomarkers to Guide Decis...


Table 2. Classification of Patients According to...


...elieves that cancer clinical trials are vital to...